Nuage Therapeutics awarded BioCentury Rising Star Award at Grand Rounds Europe 2026

The award recognises Nuage’s work as a compelling example of emerging translational innovation and underscores the potential of our proprietary technology platform to unlock new therapeutic opportunities for intrinsically disordered proteins (IDPs), a class of proteins long considered beyond the reach of drug discovery.

Receiving this recognition among such an outstanding group of innovative biotech companies is a tremendous honour and further validates our mission to usher in a new wave of transformational precision therapies for aggressive cancers with limited treatment options. By unlocking the therapeutic potential of protein disorder, Nuage Tx is helping turn a long-standing challenge in drug discovery into a powerful therapeutic opportunity.

We would like to thank BioCentury for this recognition and everyone who took the time to engage with our science during the conference.